Category Archives: Anlage Philosophie

Update Handelsbanken – HOLD

Handelsbanken Update:

2018 was on the surface a solid year for Handelsbanken. According to the 2018 annual report, operating profit increased by +5% and net income by +8%, top line by +5%. ROE was 12,8% which is below my assumed 15% but still a remarkably good number for a large bank.

Just looking at the bottom line, the first quarter of Handelsbanken looks great:  Net income up +19%, operating profit up +18%. However top line only grew at +4% (vs. Q1 2018).

However this is solely a function of the fact that the bank reversed their provision into the Oktogonen pension fund for employees which they clearly state in the quarterly report:

Read more

Online Travel Updates (Expedia, Booking, Tripadvisor, Trivago & AirBNB / Google)

Expedia 

I invested into Expedia in February 2018 after the stock had become cheap enough. The idea was that a stock in a secular growth sector (online travel) should do well in the long run. After pretty decent fulll year 2018 numbers, with double digit increases in both, top and bottom, line, the first quarter 2019 showed a clear slowdown. Topline growth slowed to ~4%. Excluding Trivago which is still shrinking, topline sales would have grown +6%. Underlying profitability has improved although the first quarter is always the weakest one.

What I found interesting is the fact that Expedia performed better than Booking com. Here is a stock price comparison (including Tripadvisor  and Trivago):

Read more

Deutsche Familienversicherung AG: Europe’s leading Insurtech or “Lipstick” on an ordinary Insurance company ?

Deutsche Familenversicherung AG (DFV) IPOed end of last year and claims to be the first stock listed “Insuretech” in Europe. The IPO was only successful at the second attempt but still they made it. In their investor presentation they even call themselves “Europe’s leading Insurtech” which is a pretty bold claim.

Excursion: What does Insurtech /Fintech mean ? And what does digital mean ?

There is clearly not general valid definition of Fintech /insurtech, but looking at the Fintech space, one would characterize these companies as technology driven companies that use technology to do things faster, cheaper and better than thier “ordinary” competitors.

Read more

Updates: Kinnevik (SELL), Vostok New Ventures (ADD), Vostok Emerging Finance (BUY)

Kinnevik

Kinenvik was an investement I first looked at in December 2017 and then decided to invest in late 2018 however only up to a 1,5% allocation.

As mentioned in the comments by a reader. since then a few things happened. From the market side, first their Zalando stock cratered and then recovered. What worries me more is the flurry of personal changes including Christina Stenbeck, the heir of the major founding family completely leaving the board. Personally; i also didn’t find their main new investment, online Grocer MatHem, very convincing. Overall, I am slightly underwhelmed from the strategic perspective. I don’t know enough about the Nordic Telecom market and if I really like Zalando, I could buy them outright. The non-listed part at Kinnevik is just to small to make a difference and the changes in the Board are hard to understand.

Read more

Special situation: Innogy Tendered Shares (IGYB) -(very) Cheap Optionality ?

Background:
The guys from Paladin AM have outlined the Innogy case very nicely on their blog (in German): Intro & Update

I’ll try to summarize it in my own words:

Innogy, the renewable energy spin-off of RWE is in the process of being taken over by competitor E.ON. E.ON in 2018 had announced to purchase the 77% stake of RWE and has offered on a voluntary basis 36.74 EUR per share which, plus the upcoming dividend adds up to a total consideration of 38,14 EUR per share before tax. The closing of the transaction is subject to a relatively complex regulatory approval process which is already facing some delays. Most experts however think that the transaction will be ultimately approved.

Read more

Position review: Van Lanschot (SELL) plus some thoughts on Unbundling /Rebundling in Banking

Background:

Having this blog is nice because I can look back at what my original ssumptions were. I bought Van Lanschot in 2013, almost 5 1/2 years ago.

This was how I “valued” Van Lanschot back then:

Valuation:

A simple, “Berkowitz style” valuation would be: Book value

With ~0.51 times book value, Van Lanschot is one of the cheapest banks in Europe. Even Greek Banks like Piraeus Bank trade higher. The current valuation is on a level with „quality banks“ like Unicredit, Espirito Santo and Credito Bergamesco.

Interestingly, the P/B multiple for listed Private banks is a lot higher. Swiss competitors Julius Baer, EFG and Banq Privee de Rothschild for instance trade on multiples between 1.1-2.0 times book, a clear premium to „normal“ banks.

So with a “normal” result, one could argue for a valuation somewhere at 1.5 x book value. Clearly, this will be a long way, one should not expect exploding profits in the next quarters. But in a time period of 3-5 years, I could imagine that the stock can triple if the turn-around is succesful. Also, when people finally realize that not every Dutch homeowner will go broke, there might be a re-rating of Dutch financial stocks in general. But this might also take time.

It would be easy to come up with a much more complicated valuation method, but I like to keep it simple. If there are no big holes in the balance sheet and costs are kept under control, equity is at a safe level, then book value should be achievable for any bank.

Read more

Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term growth opportunity ?

Disclaimer: This is not investment advice. DO YOU OWN RESEARCH !!!!

csm_zurrosegroupFINAL_01_70165d445d

The company

Zur Rose AG is a Swiss company that specializes in selling / distributing pharmaceuticals. The core business is Swiss distribution business where they distribute pharmaceuticals to Doctors, as in some parts of Switzerland, Doctors canboth, prescribe and sell pills. In 2012, Zur Rose made a smart/lucky buy: For only 25 mn EUR, they bought German based online Pharmacy Doc Morris from Celesio, a German Pharmaceuticals wholeseller that got later acquired by McKesson (I owned the stock as special situation)

Read more

April SA – Potential buyout offer from CVC: Interesting Special Situation ?

Disclaimer: This is not investment advice. Please do your own research. 

April SA is an “Old friend” on this blog. I owned the stock in the past and last time I looked at them when a rumour came up that the company is for sale in late October.

This is what I said back then:

April had shown actually pretty decent growth in Q3 and I actually considered buying some shares but maybe this is not so sustainable and the founder wants to sell before it is getting worse again ? Who knows…

My fundamental assessment of April is that they have a strong core business (French Broker) but have over extended themselves internationally and the founder, Bruno Rousset, who stepped down in 2014, does not have the energy anymore to turn this around himself.

Well, things have progressed. There had been a “beauty contest” with PE bidders and it looks now that PE shop CVC is highly interested in buying the stake of the founder and majority owner. This is from a piece of news released by April SA and  CVC end of December:

Read more

2018 Performance review – Outlook 2019

In 2018, the Value & Opportunity portfolio lost -11,3%* (including dividends, no taxes) against –15.4 % for the Benchmark (Eurostoxx50 (Perf.Ind) (25%), Eurostoxx small 200 (25%), DAX (30%), MDAX (20%)).

Links to previous Performance reviews can be found on the Performance Page of the blog.

Some other funds that I follow have performed as follows in 2018:

Partners Fund TGV: +1,74% *
Profitlich/Schmidlin: -8,27%
Squad European Convictions -9,75%
Ennismore European Smaller Cos +2,65% (in EUR)
Frankfurter Aktienfonds für Stiftungen -13,72%
Evermore Global Value  -20.92% (USD)
Greiff Special Situation -7,02%
Squad Aguja Special Situation -11,7%

*TGV Partners as of 15.12.2018, to be updated

Since inception (01.01.2011), this translates into +152,6% or +14,0% p.a. vs. 66,6% or 6,0% p.a. for the Benchmark.

Current portfolio / Portfolio transactions

The current portfolio can be seen as always on the portfolio page. I have already mentioned the 2018 transactions in the “My 22+1 stocks for 2019” post.

Read more

« Older Entries Recent Entries »